The Efficacy of Topical Agents In the Treatment of Bacterial Biofilms: An *In Vivo* Sheep Study and an *In Vitro* Study

A thesis submitted on 7th May 2010 for
The degree of Master of Surgery

Tong Ba Le, M.B.B.S. (Adelaide)

Department of Surgery, Faculty of Health Sciences, The Queen Elizabeth Hospital
The University of Adelaide, South Australia
# TABLE OF CONTENTS

**ABSTRACT** ........................................................................................................................................................................ 4

**Introduction** ........................................................................................................................................................................ 4

**Methods** ............................................................................................................................................................................... 4

**Results** ................................................................................................................................................................................ 5

**Conclusion** ........................................................................................................................................................................... 5

**ACKNOWLEDGEMENTS** ......................................................................................................................................................... 9

**CHAPTER 1** ............................................................................................................................................................................ 12

**AIMS** .................................................................................................................................................................................. 13

**CHAPTER 2** ............................................................................................................................................................................ 15

**INTRODUCTION** ................................................................................................................................................................ 15

**Chronic Rhinosinusitis (CRS)** .............................................................................................................................................. 16

- Pathogenesis ........................................................................................................................................................................... 16
- Bacteriology of CRS .................................................................................................................................................................. 17
- Clinical Management of CRS .................................................................................................................................................. 17

**Bacterial Biofilms** ................................................................................................................................................................. 18

- Definition of Biofilms and Current Concepts..................................................................................................................... 18

**Ultrastructure of Biofilms** ..................................................................................................................................................... 20

**Formation of Biofilms** .......................................................................................................................................................... 21

- Why do bacteria form biofilms? ............................................................................................................................................. 22

**Unique Properties of Biofilms** ........................................................................................................................................... 23

**Biofilms and Chronic Disease** .......................................................................................................................................... 25

**Biofilms and CRS** ................................................................................................................................................................. 26

**Detection of Biofilms** ........................................................................................................................................................... 28

- BacLight and CSLM ................................................................................................................................................................. 30

**Animal Model of CRS** ........................................................................................................................................................... 38

- Advantages of the sheep model ........................................................................................................................................... 38

**Novel anti-biofilm treatments** .......................................................................................................................................... 42

- Topical antibiotics .................................................................................................................................................................. 42

- *In vitro* investigation of anti-biofilm treatments ............................................................................................................. 42

- Loop diuretics ........................................................................................................................................................................... 44

- Surfactants .............................................................................................................................................................................. 45

- Hydropressure ......................................................................................................................................................................... 46

- Gallium Nitrate ....................................................................................................................................................................... 46

- Importance of Mucosal Injury, Restoration of Normal Mucociliary Clearance in treating CRS .................................................. 47

**Post FESS packing material** .............................................................................................................................................. 49

- Chitosan and Mucosal Healing Studies ............................................................................................................................... 49

**CHAPTER 2** ............................................................................................................................................................................ 51

**The efficacy of topical anti-biofilm agents in a sheep model of rhinosinusitis** ................................................................... 52

**ABSTRACT** ............................................................................................................................................................................ 55

**INTRODUCTION** ................................................................................................................................................................ 56

**METHODOLOGY** .................................................................................................................................................................. 58

**RESULTS** ............................................................................................................................................................................... 74

**DISCUSSION** .......................................................................................................................................................................... 80

**CONCLUSION** ....................................................................................................................................................................... 84
ABSTRACT

Introduction

Recent evidence has demonstrated the presence of bacterial biofilms on the mucosa of patients with Chronic Rhinosinusitis (CRS), suggesting their role in the pathogenesis of the condition. This thesis contains two separate studies. The studies investigated novel topical therapies by using previously established in vitro and in vivo biofilm growth and detection methods. In the first study, several different proposed anti-biofilm agents were evaluated in a sheep biofilm model, each with varying degrees of immediate and short-term success against Staphylococcus aureus biofilms. A second study was conducted to determine the in vitro anti-bacterial and anti-biofilm properties of Chitosan/Dextran (CD) gel, a novel chitosan-based product with remarkable mucosal healing and haemostatic properties.

Methods

Three alternative anti-biofilm treatments: Mupirocin, CAZS (Citric Acid Zwitterionic Acid) and Gallium Nitrate were evaluated in a prospective randomized controlled single-blinded trial using a previously established sheep biofilm model of CRS. The sheep mucosal samples were analyzed for presence of S. aureus biofilms using BacLight staining and CLSM, and the degree of biofilm involvement was determined using FISH (Fluorescence In-Situ Hybridization).

The MIC/MBC values for CD gel and its constituents were determined by macro-dilution methods described by Jorgensen et al.[1]. Established in vitro biofilms grown from
common CRS pathogens (ATCC strains and clinical isolates) were subjected to treatment by CD gel and its components (chitosan and dextran). A 96-well micro-titre crystal-violet staining method described by O’Toole and Kolter [2] was used to determine the anti-biofilm profile of CD gel against several bacterial strains with known biofilm-forming capacity.

**Results**

Following 8 days of inoculation with *S. aureus*, all treatment groups in the sheep biofilm model showed a statistically significant reduction in biofilm surface coverage compared to no treatment. Importantly, sheep frontal sinuses treated with twice-daily mupirocin flushes for 5 days showed almost negligible biofilm growth after the follow-up period of 8 days (0.84% ± 1.25% surface area coverage per visual field).

The overall data from the *in vitro* studies suggest that CD gel has marked anti-microbial activity against planktonic and biofilm-forming bacteria. It was inhibitory and bacteriocidal at sub-clinical concentrations (25mg/mL) for all bacteria tested except for *E. coli*. When tested against a nutrient-free environment as well as a positive growth control, bacteria were essentially unable to grow in its presence.

**Conclusion**

Recalcitrant CRS is a difficult condition to manage and its pathogenesis has been closely linked to the presence of bacterial biofilms. Using a standardized biofilm sheep model of CRS, regular treatment with mupirocin flushes over a 5 day period showed an almost complete eradication of biofilms as assessed by mucosal surface coverage, with sustained effects over the 8 day period of follow-up.
Equally as efficacious in the *in vitro* setting, CD gel demonstrated potent anti-bacterial and anti-biofilm activity against a number of pathogenic organisms suspected of being involved in acute and chronic rhinosinusitis. CD gel’s favourable haemostatic and mucosal healing profile posits it as an ideal post-ESS packing material. These two topical agents therefore hold promise as effective treatment options in the management of CRS.
DECLARATION

This work contains no material which has been accepted for the award of any other degree or diploma in any university or other tertiary institution to Tong Ba Le and, to the best of my knowledge and belief, contains no material previously published or written by another person, except where due reference has been made in the text.

I give consent to this copy of my thesis, when deposited in the University Library, being available for loan and photocopying, subject to the provisions of the Copyright Act 1968.

The author acknowledges that copyright of published works contained within this thesis (as listed below*) resides with the copyright holder(s) of those works.

I also give permission for the digital version of my thesis to be made available on the web, via the University’s digital research depository, the Library catalogue, the Australasian Digital Theses Program (ADTP) and also through web search engines, unless permission has been granted by the University to restrict access for a period of time.

Tong Ba Le

7 May 2010
*Publication and Work Submitted for Publication:


Tong Le#, MBBS; Theo Athanasiadis#; MBBS; Andrew Butcher, PhD; Simon Robinson, FRACS; Steve Moratti, PhD; Lyall Hanton, PhD; Peter-John Wormald MD. The Effects of a Novel Chitosan Gel on Pathogenic Nasal Bacteria. *Submitted for publication.*

#co-first authors
ACKNOWLEDGEMENTS

The work described in this thesis was performed at the Department of Surgery; Otolaryngology, Head and Neck Surgery, at the University of Adelaide and The Queen Elizabeth Hospital.

I wish to sincerely thank the following people for their assistance and involvement in this study.

Professor Peter-John Wormald,
my supervisor, for his wisdom, guidance, encouragement and support.

Dr Alkis Psaltis,
my co-reseacher, for his companionship, enormous intellectual ability, motivation and inspiration during the tough times.

Dr Theodore Athanisiadis,
my co-researcher, for his friendship, intellect and patience. A scholar and a family man, who makes it look so easy.

Dr Lorwai Tan,
my co-supervisor, for her commitment to education, and encouragement.
Dr Andrew Butcher,
Director of The Department of Microbiology at The Queen Elizabeth Hospital, for his
guidance and assistance through all the microbiological procedures of these studies. His
support and service to the Otolaryngology department is invaluable.

Ms Lyn Martin,
Secretary of The Department of Otolaryngology, Head and Neck Surgery, The Queen
Elizabeth Hospital, for her patience, ingenuity, and unconditional support throughout our
growth as researchers and clinicians.

The staff, at Adelaide Microscopy,
The University of Adelaide, for their teaching of the fine art of microscopy.

The staff, at The Animal House,
The Queen Elizabeth Hospital, Woodville South,
for all their hard work and endless dedication to the welfare of the subjects.

My Family,
for all their support and patience.
PREFACE

A significant portion of the work described within this thesis has been published.


Tong Le#, MBBS; Theo Athanasiadis#; MBBS; Andrew Butcher, PhD; Simon Robinson, FRACS; Steve Moratti, PhD; Lyall Hanton, PhD; Peter-John Wormald MD. The Effects of a Novel Chitosan Gel on Pathogenic Nasal Bacteria. *Submitted for publication.*

#co-first authors